Compare · JNJ vs ZSTK
JNJ vs ZSTK
Side-by-side comparison of Johnson & Johnson (JNJ) and ZeroStack Corp. (ZSTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and ZSTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $634.06B, about 179892.2x ZSTK ($3.5M).
- Over the past year, JNJ is up 56.5% and ZSTK is down 94.0% - JNJ leads by 150.5 points.
- JNJ has been more active in the news (13 items in the past 4 weeks vs 8 for ZSTK).
- JNJ has more recent analyst coverage (25 ratings vs 0 for ZSTK).
- Company
- Johnson & Johnson
- ZeroStack Corp.
- Price
- $263.42+1.56%
- $1.47-4.87%
- Market cap
- $634.06B
- $3.5M
- 1M return
- +9.30%
- -59.97%
- 1Y return
- +56.49%
- -94.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 13
- 8
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- SEC Form 10-Q filed by Johnson & Johnson
- TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
- Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
- EVP, Global Corp Affairs Broadhurst Vanessa exercised 23,054 shares at a strike of $130.77 and sold $5,792,686 worth of shares (23,054 units at $251.27) (SEC Form 4)
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
Latest ZSTK
- ZeroStack Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets
- Executive Chairman Heinrich Michael bought $3,479,013 worth of shares (4,608,575 units at $0.75) (SEC Form 4)
- CEO Reis-Faria Daniel exercised 5,954,743 in-the-money shares at a strike of $0.00 (SEC Form 4)
- SEC Form 4 filed by CFO Vaiman Dany
- ZeroStack Corp. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- ZeroStack Announces Results of 2026 Annual and Special Meeting of Shareholders, Provides Phatebo Purchase Orders Update and Announces Closing of Previously Announced Cryptocurrency Financing
- ZeroStack Corp. Secures Purchase Orders for up to US$14.7 Million of Inventory from Two Pharmaceutical Companies
- DeFi Dev Corp. Announces Strategic Leadership Transition of DisclaimerCoin (DONT) to Dedicated Ecosystem Team
- SEC Form EFFECT filed by ZeroStack Corp.
- SEC Form 424B3 filed by ZeroStack Corp.